REFERENCES
1. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017;18:3-9.
2. Hatoum A, Mohammed R, Zakieh O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res 2019;11:1843-55.
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
4. Hashmi FA, Salim A, Shamim MS, Bari ME. Biological characteristics and outcomes of Gliosarcoma. J Pak Med Assoc 2018;68:1273-75.
5. Song A, Andrews DW, Werner-Wasik M, Kim L, Glass J, et al. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. Radiother Oncol 2019;132:135-41.
6. Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol 2018;20:1383-92.
7. Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol 2019; doi: 10.1093/neuonc/noz040.
8. Laub CK, Stefanik J, Doherty L. Approved treatments for patients with recurrent high-grade gliomas. Semin Oncol Nurs 2018;34:486-93.
9. Serventi J, Behr J. Surgery and evidence-based treatments in patients with newly diagnosed high-grade glioma. Semin Oncol Nurs 2018;34:443-53.
10. Thon N, Tonn JC, Kreth FW. The surgical perspective in precision treatment of diffuse gliomas. Onco Targets Ther 2019;12:1497-1508.
11. Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 2011;13:428-36.
12. Khan KA, Abbasi AN, Ali N. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. J Coll Physicians Surg Pak 2014;24:935-9.
13. Donovan LE, Lassman AB. Chemotherapy treatment and trials in low-grade gliomas. Neurosurg Clin N Am 2019;30:103-9.
14. Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, et al. Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology 2019;33:91-100.
15. Liu R, Li W, Tao B, Wang X, Yang Z, et al. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance. Nat Commun 2019;10:991.
16. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, et al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 2019;9:41.
17. Raguz S, Yague E. Resistance to chemotherapy: new treatments novel insights into an old problem. Brit J Cancer 2008;99:387-91.
19. Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 2014;6:149-70.
20. Neal A, Moffat BA, Stein JM, Nanga RPR, Desmond P, et al. Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging. Neuroimage Clin 2019;22:101694.
21. Shen X, Voets NL, Larkin SJ, de Pennington N, Plaha P, et al. A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy. Metabolites 2019;9:35.
22. Hilario A, Hernandez-Lain A, Sepulveda JM, Lagares A, Perez-Nuñez A, et al. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. Neurocirugia (Astur) 2019;30:11-8.
23. Fahlström M, Blomquist E, Nyholm T, Larsson EM. Perfusion magnetic resonance imaging changes in normal appearing brain tissue after radiotherapy in glioblastoma patients may confound longitudinal evaluation of treatment response. Radiol Oncol 2018;52:143-51.
24. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102:16759-64.
25. Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26:3387-94.
26. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-9.
27. Nowosielski M, Recheis W, Goebel G, Güler O, Tinkhauser G, et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011;53:291-302.
28. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2:581-7.
29. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1:336-43.
30. Schepkin VD, Ross BD, Chenevert TL, Rehemtulla A, Sharma S, et al. Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med 2005;53:85-92.
31. Laymon CM, Oborski MJ, Lee VK, Davis DK, Wiener EC, et al. Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. Magn Reson Imaging 2012;30:1268-78.
32. Thulborn KR, Davis D, Adams H, Gindin T, Zhou J. Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn Reson Med 1999;41:351-9.
33. Schepkin VD, Elumalai M, Kitchen JA, Qian C, Gor’kov PL, et al. In vivo chlorine and sodium MRI of rat brain at 21.1 T. MAGMA 2014;27:63-70.
34. Schepkin VD, Lee KC, Kuszpit K, Muthuswami M, Johnson TD, et al. Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 2006;19:1035-42.
35. Schepkin VD, Chenevert TL, Kuszpit K, Lee KC, Meyer CR, et al. Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging 2006;24:273-8.
36. Bartha R, Megyesi JF, Watling CJ. Low-grade glioma: correlation of short echo time 1H-MR spectroscopy with 23Na MR imaging. AJNR Am J Neuroradiol 2008;29:464-70.
37. Ouwerkerk R, Bleich KB, Gillen JS, Pomper MG, Bottomley PA. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology 2003;227:529-37.
38. Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, et al. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol 2011;46:539-47.
39. Nunes Neto LP, Madelin G, Sood TP, Wu CC, Kondziolka D, et al. Quantitative sodium imaging and gliomas: a feasibility study. Neuroradiology 2018;60:795-802.
40. Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, et al. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 2006;66:4687-92.
41. Schepkin VD. Sodium MRI of glioma in animal models at ultrahigh magnetic fields. NMR Biomed 2015;29:175-86.
42. Schepkin VD, Bejarano FC, Morgan T, Gower-Winter S, Ozambela M Jr, et al. In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T. Magn Reson Med 2012;67:1159-66.
43. Budinger TF, Bird MD, Frydman L, Long JR, Mareci TH, et al. Toward 20 T magnetic resonance for human brain studies: opportunities for discovery and neuroscience rationale. MAGMA 2016;29:617-39.
45. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Gen Devel 2008;18:54-61.
46. Koukourakis M, Tsolou A, Pouliliou S, Lamprou I, Papadopoulou M, et al. Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. Biochem Biophys Res Commun 2017;491:932-8.
47. Venneti S, Thompson CB. Metabolic teprogramming in brain tumors. Annu Rev Pathol 2017;12:515-45.
48. Libby CJ, Tran AN, Scott SE, Griguer C, Hjelmeland AB. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. Biochim Biophys Acta Rev Cancer 2018;1869:175-88.
49. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
50. Fogg VC, Lanning NJ, MacKeigan JP. Mitochondria in cancer: at the crossroads of life and death. Chin. J. Cancer 2011;30:526-539.
51. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer’s Achilles’ heel. Cancer Cell 2008;13:472-82.
52. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin. Cell & Dev Biol 2012;23:352-361.
53. Yuen CA, Asuthkar S, Guda MR, Tsung AJ, Velpula KK. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept. CNS Oncol 2016;5:101-8.
54. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012;15:827-37.
55. Mischel PS. HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metab 2012;15:789-90.
56. Oliva C, Nozell S, Diers A, McClugage S, Sarkaria J, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 2010;285:39759-67.
57. Oliva C, Moellering D, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas Is associated with I\increased mitochondrial coupling and decreased ROS production. PloS One 2011;6:e24665.
58. Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 2010;12:727-39.
59. St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol 2015;125:91-102.
60. Shen H, Decollogne S, Dilda PJ, Hau E, Chung SA, et al. Dual-targeting of aberrant glucose metabolism in glioblastoma. J Exp Clin Cancer Res 2015;34:14.
61. .
62. Katz J, Lee WNP, Wals PA, Bergner EA. Studies of glycogen synthesis and the Krebs cycle by mass isotopomer analysis with [U-13C] glucose in rats. J Biol Chem 1989;264:12994-13004.
63. Katz J, Walls P, Lee WNP. Isotopomer studies of gluconeogenesis and the krebs cycle with 13C-labeled lactate. J Biol Chem 1993;268:25509-21.
64. Fernandez CA, Des Rosiers C. Modeling of liver citric acid cycle and gluconeogenesis based on 13C mass isotopomer distribution analysis of intermediates. J Biol Chem 1995;270:10037-42.
65. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31-4.
66. Kastl L, Brown I, Schofield A. Altered DNA methylation is associated with docetaxol resistance in human breast cancer cells. Int J Oncol 2010;36:1235-41.
67. Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L, Perez-Cardenas E, Trejo-Becerril C, et al. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PloS One 2012;7:e29181.
68. Hervouet E, Cheray M, Vallette FM, Cartron PF. DNA methylation and apoptosis resistance in cancer cells. Cells 2013;2:545-73.
69. Bruzzone MG, Eoli M, Cuccarini V, Grisoli M, Valletta L, et al. Genetic signature of adult gliomas and correlation with MRI features. Expert Rev Mol Diagn 2009;9:709-20.
70. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010;120:567-84.
71. Bartesaghi S, Graziano V, Galavotti S, Henriquez NV, Betts J, et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proc Natl Acad Sci U S A 2015;112:1059-64.
72. Stepanenko AA, Andreieva SV, Korets KV, Mykytenko DO, Baklaushev VP, et al. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. Cancer Cell Int 2016;16:36.
73. Immanuel SRC, Ghanate AD, Parmar DS, Marriage F, Panchagnula V, et al. Integrative analysis of rewired central metabolism in temozolomide resistant cells. Biochem Biophys Res Commun 2018;495:2010-6.
74. Suwala AK, Koch K, Rios DH, Aretz P, Uhlmann C, et al. Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro. Oncotarget 2018;9:22703-16.
75. Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, et al. Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep 2017;19:1858-73.
76. Beig N, Patel J, Prasanna P, Hill V, Gupta A, et al. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep 2018;8:7.
77. Agrawal R, Pandey P, Jha P, Dwivedi V, Sarkar C, et al. Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing. BMC Genomics 2014;15:686.
78. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2012;81:103-22.
79. Tabet A, Jensen MP, Parkins CC, Patil PG, Watts C, et al. Designing next-generation local drug delivery vehicles for glioblastoma adjuvant chemotherapy: lessons from the clinic. Adv Healthc Mater 2019;8:e1801391.
80. Ius T, Cesselli D, Isola M, Toniato G, Pauletto G, et al. Combining clinical and molecular data to predict the benefits of carmustine wafers in newly diagnosed high-grade gliomas. Curr Treat Options Neurol 2018;20:3.
81. Sippl C, Ketter R, Bohr L, Kim YJ, List M, et al. miRNA-181d expression significantly affects treatment responses to carmustine wafer implantation. Neurosurgery 2019;85:147-55.
82. Zhang L, Yang H, Zhang W, Liang Z, Huang Q, et al. Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance. J Neurochem 2017;142:574-88.
83. Meco D, Di Francesco AM, Melotti L, Ruggiero A, Riccardi R. Ectopic nerve growth factor prevents proliferation in glioma cells by senescence induction. J Cell Physiol 2019;234:6820-30.
84. Persaud SD, Park SW, Ishigami-Yuasa M, Koyano-Nakagawa N, Kagechika H, et al. All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation. Sci Rep 2016;6:27678.
85. Ikemori RY, Machado CM, Furuzawa KM, Nonogaki S, Osinaga E, et al. Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival. PLoS One 2014;9:e111592.
